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Involvement of PPARc in Oxidative Stress-Mediated
Prostaglandin E2 Production in SZ95 Human
Sebaceous Gland Cells
Qiwei Zhang1, Holger Seltmann2, Christos C. Zouboulis2 and Raymond L. Konger1,3
Peroxisome proliferator-activated receptor gamma (PPARg) is thought to play a role in sebaceous gland cell
function. We previously demonstrated in human epidermoid carcinoma KB cells that UVB irradiation activates
PPARg via the generation of multiple oxidized glycerophosphocholine species with PPARg ligand activity. UVB-
induced cyclooxygenase 2 (COX-2) expression was also shown to be PPARg-dependent. We therefore reasoned
that PPARg activation and PPARg-dependent COX-2 expression may occur as a general consequence of oxidative
stress. The present studies were designed to examine the effects of the oxidant tert-butylhydroperoxide (TBH)
on PPARg activation and COX-2 expression in SZ95 sebocytes. We first verified that functional PPARg is
expressed and activated by UVB irradiation in these cells. We next demonstrated that TBH increased PPARg
reporter activity in SZ95 sebocytes. Increased COX-2 protein, mRNA expression, and prostaglandin E2 (PGE2)
production was observed after TBH or PPARg agonist treatment. The ability of PPARg agonists and TBH to induce
COX-2 expression and PGE2 production was blocked by pretreatment with the specific PPARg antagonist
GW9662. Finally, TBH and PPARg agonists failed to elicit a PGE2 response in SZ95 sebocytes stably expressing a
dominant-negative PPARg. This study illustrates the importance of the PPARg system in regulating cellular
responses to oxidative stress.
Journal of Investigative Dermatology (2006) 126, 42–48. doi:10.1038/sj.jid.5700028
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) were first
cloned in the early 1990s. They were identified as targets of
various xenobiotic and oxidized lipid molecules that are
involved in regulating the formation of intracellular orga-
nelles, called peroxisomes, which are involved in lipid
metabolism (reviewed in Kuenzli and Saurat, 2003). PPARs
are members of the ligand-activated nuclear hormone
receptor superfamily, which include receptors for thyroid
hormones, retinoids, steroid hormones, and vitamin D. Three
different PPAR subtypes have been cloned: PPARa, PPARb/d,
and PPARg. All are nuclear transcription factors that require
heterodimerization with the retinoid X receptors for tran-
scriptional activity. Upon heterodimerization, PPAR:retinoid
X receptor heterodimers activate transcription by binding to
specific DNA sequences, called peroxisome proliferators
response elements (PPRE), in the promoter region of target
genes.
Natural PPARg ligands are thought to include metabolites
of both cyclooxygenase (COX) and lipooxygenase pathways,
including the cyclopentanone prostaglandin (PG), 15-deoxy-
D12,14-prostaglandin J2, and the 13-hydroxyoctadecadienoic
acid. However, the high concentrations needed to activate
PPARg, as well as nonspecific effects, raise doubts as to the
physiological relevance of these agents. More recently,
it has been determined that the oxidized alkyl phospholipid,
1-hexadecyl 2-azelaoyl phosphatidylcholine (azPC),
which is derived from oxidized low-density lipoprotein,
may represent an endogenous, physiologically relevant,
PPARg ligand with an EC50 of approximately 40 nM
(Davies et al., 2001). Within cells, azPC is also derived
from oxidation of 1-hexadecyl 2-arachidonoyl-glyceropho-
sphocholine, a minor constituent of cellular lipids (Zhang
et al., 2005). Importantly, we have previously demonstrated
that azPC is produced following UVB irradiation of
1-hexadecyl 2-arachidonoyl-glycerophosphocholine (Zhang
et al., 2005). In addition, a number of synthetic PPARg
agonists have been developed that are widely used in the
treatment of type II diabetes. This thiazolidinedione class of
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antidiabetic compounds includes the potent PPARg ligand
ciglitazone.
PGs are lipid mediators synthesized in response to
numerous growth factors and environmental stimuli. The
production of PGs is dependent on the activity of COX
enzymes (COX-1 and COX-2) (Ota et al., 2002). COX-1 is
generally constitutively expressed, whereas COX-2 is in-
duced by various mitogens, hormones, and environmental
stimuli. Increased COX-2 expression and elevated prosta-
glandin E2 (PGE2) are commonly observed in epithelial
malignancies (Buckman et al., 1998; Nijsten et al., 2004).
PGs and COXs are important in epithelial tumorigenesis, as
demonstrated by the potent chemopreventive capacity that
COX inhibitors exert in various malignancies, including skin
cancer (Fischer et al., 1999; Pentland et al., 1999; Ota et al.,
2002). Finally, although the COX-2 promoter is known to
contain a 50-PPRE, its role in regulating COX-2 mRNA
expression has only recently been examined (Pontsler et al.,
2002).
We have recently demonstrated, in the epidermoid
carcinoma cell line (KB), that UV exposure results in the
production of oxidized lipid species, including azPC, with
potent PPARg ligand activity (Zhang et al., 2005). As this
activity was blocked by treating cells with the antioxidant,
Troloxs, this strongly suggests that PPARg agonist activity
occurred as a result of UV-generated reactive oxygen species.
In addition, we demonstrated that PPARg activation in KB
cells is an essential step in UVB-induced COX-2 expression.
We therefore hypothesized that PPARg activation and PPARg-
mediated induction of COX-2 may occur as a generalized
response to other types of oxidative stress.
As PPARg is prominently expressed in the pilosebaceous
glands and in SZ95 sebocytes, we therefore chose to examine
this hypothesis in the SZ95 sebaceous gland cell line (Chen
et al., 2003; Alestas et al., submitted for publication). In
addition, the most common disease of the pilosebaceous
gland is acne vulgaris, the pathogenesis of which is
dependent on ductal hyperplasia and hyperkeratinization,
excess sebum production, inflammation, and the presence of
propionibacteria (Harper and Thiboutot, 2003; Holland et al.,
2004; Zouboulis et al., 2005). Given that PPARg and COX-2
are known to be involved in inflammation and sebocyte
growth and differentiation, it is likely that a PPARg–COX-2
signaling system would play an important role in sebocyte
biology and pathology (Rosenfield et al., 1998, 2000; Kim
et al., 2001; Downie et al., 2004; Kuenzli and Saurat, 2004;
Iwata et al., 2005).
The importance of COX-2 in sebaceous gland develop-
ment is seen in transgenic mice with targeted overexpression
of the inducible COX-2 isoform (Neufang et al., 2001;
Muller-Decker et al., 2002). These mice develop sebaceous
gland hyperplasia, sebaceous gland adenomas, and increased
sebum production, suggesting an important role for COX-2
and PGs in sebocyte proliferation, lipid metabolism,
and tumorigenesis. We therefore sought to determine
whether oxidative stress induces PPARg activation and
increased COX-2 expression and activity in human sebocytes
in vitro.
RESULTS
Identification of functionally active PPARc protein in epidermal
cells
It has previously been reported that SZ95 sebocytes express
PPARg protein (Chen et al., 2003). PPARg1 and PPARa are the
most abundant PPAR isoforms in SZ95 sebocytes (Alestas
et al., submitted for publication). Thus, the first studies were
designed to confirm that SZ95 sebocytes contain the
functional PPARg system. Total cellular protein was isolated
and PPARg protein was shown to be present in SZ95 cell lines
(Figure 1a). Primary human keratinocytes and human
epidermal carcinoma cells (KB cells) were also examined as
these cells have also been reported to express PPARg
(Rosenfield et al., 2000; Zhang et al., 2005). We next sought
to determine whether PPARg was functionally active in SZ95
sebocytes. To accomplish this, we transfected SZ95 sebocytes
with a PPRE-luciferase reporter construct (Davies et al.,
2001). In Figure 1b, we show that the specific PPARg agonists
azPC and ciglitazone were able to induce agonist-dependent
luciferase expression in SZ95 sebocytes (Figure 1b). It should
be noted that the PPRE reporter used does not result in high
levels of promoter activity (only 2- to 3-fold increases),
findings consistent with the use of this gene reporter system in
other cell types (Davies et al., 2001; Zhang et al., 2005).
PPARc activation is sufficient to induce COX-2 expression
in SZ95 sebocytes
In previous studies using KB cells, we demonstrated that
PPARg agonists were capable of augmenting phorbol ester-
induced COX-2 expression (Zhang et al., 2005). However,
PPARg agonists alone had no effect on COX-2 expression in
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Figure 1. Functionally active PPARc is present in the human SZ95 cell line.
(a) Forty micrograms of cellular protein isolated from KB, primary human
keratinocyte (PHK), and SZ95 sebocytes was separated on a 10% SDS-PAGE
and PPARg immunoreactivity was determined using a polyclonal antibody.
(b) SZ95 sebocytes co-transfected with PPRE-luciferase reporter and
b-galactosidase (b-gal) plasmids were treated variously with vehicle control
(CON, 0.4% ethanol), specific PPARg agonists 1 mM azPC or 20mM ciglitazone
(CIG) for 24 hours. The cells were harvested for luciferase activity assay
and normalized to b-gal activity. The values shown are mean7SD and
are representative of three separate experiments (*Po0.05).
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these cells. In contrast, we demonstrate in Figure 2a that the
addition of ciglitazone or azPC alone is sufficient to induce
COX-2 expression in the absence of phorbol ester. For these
studies, SZ95 sebocytes were treated with ciglitazone, azPC,
or phorbol-12-myristate-13-acetate (PMA) as a positive
control for induction of COX-2. To confirm that PPARg
agonist-induced COX-2 induction was due to PPARg activa-
tion, the specific PPARg inhibitor GW9662 was used
(Leesnitzer et al., 2002). Significantly, pretreatment of SZ95
sebocytes with the PPARg antagonist GW9662 blocked the
ability of ciglitazone to augment COX-2 expression (Figure
2b). In contrast, pretreatment with GW9662 did not alter
PMA-induced COX-2 expression.
UVB irradiation of SZ95 sebocytes produces PPARc agonistic
activity that is transferable in cellular homogenates
We have previously demonstrated, in human epidermoid
carcinoma KB cells, that UVB irradiation could induce the
generation of lipid species with PPARg agonist activity (Zhang
et al., 2005). We therefore examined whether UVB irradia-
tion of SZ95 sebocytes would result in a similar production of
a dose-dependent PPARg agonist activity that could be
transferred via cellular homogenates. In Figure 3a and b,
we demonstrate that homogenates prepared from UVB-
irradiated SZ95 sebocytes contained potent PPARg agonist
activity, with a dose of 4,000 J/m2 inducing luciferase activity
at levels equivalent to 20 mM ciglitazone. This was shown in
both SZ95 sebocytes and KB cells expressing the PPRE-
luciferase reporter.
The potent oxidant tert-butylhydroperoxide generates a PPARc
agonistic activity in SZ95 sebocytes
We have previously demonstrated that oxidative stress
mediated by UVB exposure induces PPARg ligand production
in KB cells. In Figure 4, we demonstrate that this effect
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Figure 2. PPARc agonists induce COX-2 protein expression through
activation of PPARc in SZ95 sebocytes. (a) SZ95 sebocytes were treated with
20mM ciglitazone, 1mM azPC, or 100 nM PMA as a positive control for
induction of COX-2. Approximately 40 mg cellular protein was isolated and
separated on 10% SDS-PAGE; COX-2-immunoreactivity was determined
using a polyclonal antibody. (b) SZ95 sebocytes were pretreated with vehicle
control or 1 mM GW9662 (GW) for 1 hour, and then treated with 20mM
ciglitazone or 100 nM PMA. Forty micrograms of cellular protein was isolated
and separated on 10% SDS-PAGE and COX-2 immunoreactivity was
determined using a polyclonal antibody.
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Figure 3. Cellular homogenates from UVB-irradiated SZ95 cells contain PPARc agonistic activity. SZ95 cells (a) or KB cells (b) co-transfected with PPARg
luciferase reporter and b-gal plasmids were treated with cell homogenate derived from unirradiated SZ95 cells, or cells irradiated with various doses of UVB, or
treated with 20mM ciglitazone (CIG) as a positive control for PPARg activation. Cells were harvested 24 hours after treatment for luciferase and b-gal activity
assay. The values shown are mean7SD and are representative of three separate experiments (*Po0.05).
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appears to be common to different oxidative stressors. In this
case, the lipid-soluble oxidant tert-butylhydroperoxide (TBH)
was capable of generating a dose-dependent PPARg agonistic
activity. Doses of 10–20 mM resulted in PPRE-luciferase
activity equivalent to that observed for the PPARg agonist
ciglitazone.
Both ciglitazone and TBH induce COX-2 mRNA in
a PPARc-dependent manner
Previous studies have reported that the COX-2 promoter
contains a known PPRE consensus site (Meade et al., 1999).
Thus, the next studies were designed to determine whether
the treatment of SZ95 sebocytes with the oxidative stressor
TBH would induce PPARg-dependent COX-2 mRNA expres-
sion. In Figure 5, we utilized quantitative RT-PCR to
demonstrate that ciglitazone, as well as TBH treatment,
induced COX-2 mRNA expression in SZ95 sebocytes. This
induction of COX-2 mRNA by ciglitazone was completely
blocked by pretreatment of PPARg-specific antagonist
GW9662. GW9662 was also able to inhibit TBH-induced
COX-2 expression significantly.
PPARc activity is critical for oxidative stress-induced PGE2
production in SZ95 sebocytes
Previous studies in KB cells indicated that UVB-induced
epidermal PGE2 formation is dependent on the PPARg system
(Zhang et al., 2005). In Figure 6, we demonstrate that the
PPARg agonist ciglitazone as well as oxidative stressors TBH
and UVB were able to significantly increase PGE2 production
over 8 hours in SZ95 sebocytes. The calcium ionophore
A23187, which induces calcium-dependent eicosanoid
synthesis, was used as a positive control. Importantly, the
PPARg antagonist GW9662 was able to block PPARg agonist
and oxidative stress-induced PGE2 production, but not
ionomycin-induced PGE2 production. There was no signifi-
cant stimulation of PGE2 production by the selective PPARa
agonist (WY14643, 20 mM) or the specific PPARb/d agonist
(GW501516, 500 nM) (data not shown). We next sought to
use a molecular approach to verify that the PPARg system was
indeed involved in oxidative stress-mediated COX-2 induc-
tion and PGE2 production. To accomplish this, SZ95
sebocytes stably expressing a PPARg dominant-negative
mutant construct were produced. For control cells, cells
expressing the empty vector (pcDNA3) were also produced.
To verify that the stable SZ95/DPPARg dominant-negative
cells lacked PPARg activity, we transiently transfected the
cells with the PPARg-dependent luciferase reporter. The
DPPARg-expressing cells lacked luciferase reporter expres-
sion in response to ciglitazone or azPC (data not shown). As
shown in Figure 7, ciglitazone, TBH, or UVB irradiation-
induced PGE2 production was markedly suppressed in SZ95/
DPPARg dominant-negative cells in comparison to SZ95/
pcDNA3 control cells. In contrast, PGE2 production induced
by calcium ionophore A23187 was not affected by the
presence of a mutant PPARg system. Altogether, these studies
confirm that the PPARg system, activated by specific agonists
or agonistic activity generated by oxidative stress, can
modulate COX-2 expression and PGE2 production in SZ95
sebocytes.
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Figure 4. PPRE-LUC reporter assay demonstrates that direct-acting oxidative
stressor TBH produces PPARc agonistic activity in SZ95 sebocytes in a dose-
dependent manner. SZ95 sebocytes co-transfected with PPARg luciferase
reporter and b-gal plasmids were treated with various doses of TBH or 20 mM
ciglitazone as a positive control for PPARg activation. Cells were harvested
24 hours after treatment for luciferase and b-gal activity assay. The values
shown are mean7SD and are representative of three separate experiments
(*Po0.05).
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Figure 5. Specific PPARc antagonist GW9662 blocks oxidative stress-
induced COX-2 mRNA induction. SZ95 sebocytes were pretreated with
vehicle control or 1 mM GW9662 for 1 hour, and then exposed to 20mM
ciglitazone, 10mM TBH, or 100 nM PMA for 6 hours. Total cellular RNA
was extracted and quantitative RT-PCR was performed for COX-2 mRNA
expression. Cycle threshold units were then converted into concentration
units using a log standard curve. Relative COX-2 expression is normalized to
18S ribosomal RNA. Results represent the mean7standard error of mean of
two experiments carried out in duplicate or triplicate (*Po0.05; **Po0.01).
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Figure 6. Specific PPARc antagonist GW9662 blocks oxidative stress-
induced PGE2 production. SZ95 sebocytes were pretreated with vehicle
control or GW9662 1 mM for 1 hour, and then treated with 20 mM ciglitazone,
10mM TBH, 500 nM calcium ionophore A23187, or exposed to 600 J/m2 UVB
irradiation; PGE2 production was assayed in the tissue culture supernatants
after 8 hours. The values of PGE2 expression shown are mean7SD and are
representative of three independent experiments (*Po0.05).
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DISCUSSION
We have previously reported that UVB exposure activates
PPARg via production of multiple mostly uncharacterized
oxidized glycerophosphocholine species. Importantly, one of
these oxidized lipids was identified as azPC, which has
previously been identified as an endogenously produced
PPARg ligand. In addition, COX-2 is well known to be
induced in the epidermis by UVB treatment. Importantly, we
demonstrated that UVB-mediated COX-2 induction is
mediated by PPARg activation. In this report, we further
extend these studies to show that PPARg is activated as a
general response to multiple oxidative stressors, including the
application of the lipid-soluble oxidizing agent TBH. In
addition, both ciglitazone and azPC were capable of
inducing COX-2 expression in SZ95 sebocytes in the absence
of a costimulatory signal. This differs from our previous
findings in KB epidermal carcinoma cells, in which COX-2
induction by PPARg agonists required a costimulation with
phorbol ester or IL1-b. Our data add to a growing body of
evidence that PPARg activation can act to either induce and
repress COX-2 expression in a cell- and tissue-type-specific
manner (Meade et al., 1999; Liang et al., 2001; Yang and
Frucht, 2001; Pontsler et al., 2002; Bishop-Bailey and
Warner, 2003; Hinz et al., 2003; Mendez and LaPointe,
2003; Sabichi et al., 2004).
These data add a stone to the mosaic of PPARg relevance
to sebocyte biology. Natural and synthetic PPAR-g1 ligands
have been shown to both enhance and reduce lipogenesis in
sebaceous gland cells or isolated human sebaceous glands
(Rosenfield et al., 1998; Downie et al., 2004; Iwata et al.,
2005). In addition, in mouse epidermis, overexpression of
COX-2 is associated with a cutaneous phenotype demon-
strating sebaceous gland hypertrophy and greasy hair,
suggestive of increased sebum production (Neufang et al.,
2001; Muller-Decker et al., 2002). Thus, our findings that
PPARg activation induces COX-2 expression in SZ95
sebocytes may indicate a PPARg/COX-2-mediated pathway
regulating sebocyte proliferation and/or lipogenesis. These
data fit well with the clinical finding that COX-2 expression is
upregulated in the sebaceous glands of acne-involved skin
(Alestas et al., submitted for publication).
Diseases of the pilosebaceous gland include the common
disease acne vulgaris. Although not life-threatening, acne can
result in facial scarring and even relatively minor acne is
significantly associated with psychosocial well-being, includ-
ing lowered self-esteem, increased levels of anxiety and
depression, and increased suicidal ideation (Gupta and
Gupta, 2003; Yazici et al., 2004). It is interesting that two
well-known treatments for acne are retinoids and benzoyl
peroxide, which induces lipid peroxidation in keratinocytes
(Babich et al., 1996). Given that PPARs heterodimerize with
retinoid X receptors and oxidative stress activates a PPARg–-
COX-2 signaling pathway, this strongly suggests that the
PPARg–COX-2 signaling pathway may play a role in acne
pathogenesis.
In addition to sebaceous gland hypertrophy, mice over-
expressing COX-2 in the skin also exhibited increased rates of
sebaceous gland adenomas (Neufang et al., 2001; Muller-
Decker et al., 2002). Although uncommon, sebaceous
carcinoma is an aggressive carcinoma, with frequent local
and distant metastasis at the time of diagnosis (Omura et al.,
2002; Bordea et al., 2004). Moreover, the chronic use of
strong oxidants like benzoyl peroxide is also associated with
increased risk for cutaneous neoplasia (Athar et al., 1989).
Given the growing evidence that COX-2 plays a causal role in
epithelial tumorigenesis, it is unclear whether chronic or
repeated benzoyl peroxide exposure may increase the risk for
neoplastic disease in the pilosebaceous gland or surrounding
epidermis via PPARg stimulation and subsequent COX-2
elevation.
In conclusion, we show clear evidence in a second
independent cell line that PPARg is activated by UVB
irradiation. Moreover, activation of PPARg appears to occur
as a general response to oxidative stress, as the potent lipid-
soluble oxidant TBH was also capable of activating PPARg. In
addition, we show that the ability of oxidative stress to induce
COX-2 expression is PPARg dependent. However, the ability
of PPARg agonists to stimulate COX-2 expression in the
absence of costimulatory signals appears to be dependent on
cell type. In addition, it is unclear whether oxidative stress
would act to suppress COX-2 expression in those cells or
tissues in which PPARg agonists have been shown to inhibit
COX-2 expression. It does seem apparent, however, that the
mechanisms by which PPARg acts to regulate COX-2
expression are likely to be complex. Not surprisingly, COX-
2 expression is influenced by multiple mechanisms, including
both positive and negative transcriptional regulators, mRNA
stability, and translational silencing (Matsuura et al., 1999;
Meade et al., 1999; Dixon et al., 2000, 2003).
MATERIALS AND METHODS
Chemicals
All chemicals were obtained from Sigma (St Louis, MO), unless
otherwise indicated. PMA was obtained from Sigma (St Louis, MO).
Ciglitazone was from Alexis Biochemicals (San Diego, CA). azPC
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Figure 7. Inhibition of PPARc in SZ95/DPPARc cells blocks oxidative stress-
induced PGE2 production. SZ95 sebocytes transfected with mutant PPARg
dominant-negative construct (SZ95/DPPARg) or control cells transfected with
vector vehicle (SZ95/pcDNA3) were treated with 20mM ciglitazone, 10mM
TBH, 500 nM calcium ionophore A23187, or exposed to 600 J/m2 UVB
irradiation; PGE2 production was assayed after 8 hours by a PGE2 ELISA kit.
The values of PGE2 expression shown are mean7SD and are representative of
three independent experiments (*Po0.05).
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was from Avantis Polar Lipids Inc. (Alabaster, AL). The PPARg-
specific antagonist GW9662 was purchased from Cayman Chemical
(Ann Arbor, MI). TBH was from MP Biomedicals Inc. (Aurora, OH).
Cell culture
The cells of the SZ95 sebaceous gland cell line are human sebocytes
immortalized by stably transfecting a primary human facial sebocyte
culture with the SV-40 large T antigen (Zouboulis et al., 1999).
Significantly, SZ95 sebocytes retain the culture morphology of
primary sebocytes as well as sebocyte-specific marker expression. In
addition, normal lipid production is observed, with both primary
sebocytes and SZ95 sebocytes producing a large number of
cytoplasmic lipid vacuoles composed of neutral lipids, including
sebum-specific lipids (Zouboulis et al., 1999). SZ95 sebocytes were
grown in Sebomeds medium (Biochrom, Berlin, Germany) supple-
mented with 10% fetal bovine serum (Intergen, Purchase, NY) and
5 ng/ml epidermal growth factor (R&D Systems, Minneapolis, MN).
The SZ95/PPARg dominant-negative model was created by transfec-
tion of SZ95 sebocytes with the PPARg dominant-negative construct
(DPPARg) encoding the mutant human PPARg with two point
mutations in the AF-2 domain, L466A and E469A (a kind gift from
Dr VKK Chatterjee, University of Cambridge, Cambridge, UK). The
human epidermoid carcinoma (KB) cells were cultured as described
previously (Zhang et al., 2005).
PPRE-luciferase reporter assay
The PPRE-luciferase reporter assay was carried out essentially as
described previously (Zhang et al., 2005).
UV irradiation studies
SZ95 cells were irradiated with UVB as previously described (Zhang
et al., 2005). The UV source was a Philips F20T12/UV-B lamp
(270–390 nm; containing 2.6% UVC, 43.6% UVB, 53.8% UVA). The
intensity of the UVB source was measured before each experiment
using an IL1700 radiometer and a SED240 UVB detector (Interna-
tional Light, Newburyport, MA) at a distance of 8 cm from the UVB
source to the monolayer of cells. Following either sham (nonirradia-
tion, left out on bench top open) or UVB irradiation, the cells were
incubated at 371C for 1 hour, and then scraped and sonicated for cell
homogenates. For assays involving PGE2 quantitation, the cells were
incubated at 371C for the time indicated in the figure legend prior to
removal of the media for PGE2 immunoassay. In this case, the
monolayer was trypsinized for total cell counts to normalize the
PGE2 results.
Immunoblotting
Cells were washed twice with ice–cold phosphate-buffered saline
and lysed with radioimmunoprecipitation assay buffer (150 mM
NaCl, 50 mM Tris–HCl, pH 8.0, 0.1% SDS, 0.5% sodium deoxycho-
late, 1% NP–40) containing 0.5 mM Pefabloc SC (Roche Diagnostics,
Indianapolis, IN) and 10 mM sodium orthovanadate for 20 minutes
on ice. COX-2 protein was separated on 10% SDS-PAGE and
expression was determined by immunoblotting with COX-2 poly-
clonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Piscataway, NJ). The expression of COX-2 protein was normalized
to the levels of housekeeping protein glyceraldehyde-3-phosphate
dehydrogenase.
PGE2 immunoassay
PGE2 production was quantitated from SZ95 sebocytes plated in a
24-well dish as previously described using an immunoassay kit (R&D
Systems, Minneapolis, MN) (Zhang et al., 2005).
RNA isolation and quantitative reverse transcription-PCR
Total RNA was first isolated and purified from cultured cells using
an RNeasys minikit (Qiagen Inc., Valencia, CA), according to the
manufacturer’s protocol. Total RNA quantity, purity, and the absence of
ribonuclease digestion were assessed by OD260/280 absorbance
measurements and by agarose gel electrophoresis. First-strand DNA
synthesis was then performed on 5mg of RNA using a Superscript First-
Strand Synthesis System (Invitrogen, Carlsbad, CA). Reverse transcrip-
tion was primed using random hexamers. For quantitative RT-PCR,
human COX-2 was selected using a primer design software (PrimerEx-
press, PE Applied Biosystems, Foster City, CA). The COX-2 forward
primer was 50-GAATCATTCACCAGGCAAATTG-30, whereas the re-
verse primer was 50-TCTGTACTGCGGGTGGAACA-30. To normalize
for RNA loading and quality, a separate assay using primers selective
for 18S ribosomal RNA was performed. The 18S forward primer was
50-ACATCCAAGGAAGGCAGCAG-30. The 18S reverse primer was
50-TCGTCACTACCTCCCCGG-30. Real-time quantitative RT-PCR was
then performed using a Cepheid thermocycler (Fisher Scientific,
Pittsburgh, PA). Fluorescent detection of PCR products was quantitated
using SyberGreen (Qiagen SyberGreen Quantitect RT-PCR mix,
Valencia, CA). The PCR amplification was initiated using a 15 minute
951C incubation to activate the HotStarTaq DNA Polymerase. For 18S
PCR, this was followed by 35 cycles with the following thermoprofile:
951C for 30 seconds, 571C for 15 seconds, and 701C for 30 seconds.
For COX-2, the cycling parameters were 951C for 15 seconds, 57.51C
for 30 seconds, and 721C for 30 seconds. A melt curve analysis and
agarose gel electrophoresis was performed to verify the presence of a
single amplification product, 60 bp for 18S and 65 bp for the COX-2
product. For quantitative analysis of both COX-2 and 18S, a standard
curve was generated using PCR product that was band purified
following agarose gel electrophoresis. Importantly, the threshold cycle
(Ct) for all samples occurred well within the observed linear range
determined using the standard curve. Contaminating DNA in all RNA
samples was analyzed by performing qRT-PCR from RNA samples in
which a sham reverse transcription reaction was performed (no reverse
transcriptase). These no RT controls were either negative or contributed
less than 1% of the COX-2 levels for all samples.
Data analysis
Data are presented as mean7standard deviation (SD) of at least
three independent experiments. Statistical significance is assessed by
the Student’s t-test and significance is set as *Po0.05 and **Po0.01.
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